Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus versus cyclophosphamide plus steroid in steroid-resistant or steroid-dependent primary FSGS
ChiCTR-TRC-10001024Phase 4Completed
- Sponsor
- Ruijin Hospital
- Start
- Jan 2008
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus, cyclophosphamide and prednisone in focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Blood and urine routine examination, 24-hour urine protein and 3 more. Started Jan 2008; status: completed.
02
Drugs
tacrolimuscyclophosphamideprednisone
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on ChiCTR-TRC-10001024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001024.